Umayana™ and Çapa Medikal Business Cooperation
Important cooperation in the field of health from Çapa Medikal and Umayana R&D
An important step for the health sector and entrepreneurship ecosystem
Technopark Istanbul continues new collaborations for the development of deep technology entrepreneurship. One of the entrepreneurs of Technopark Istanbul Incubation Center (Cube Incubation), Umayana R&D; Collaborated with Capa Medikal, the leading supply chain management company in the healthcare industry.
Umayana R&D and Çapa Medical Cooperation signing ceremony was held at Teknopark Istanbul Incubation Center. In cooperation with Capa Medikal, Umayana R&D will produce patented products in the fields of dermatology and dentistry, as well as products that prevent and heal wounds that occur during radiotherapy and chemotherapy treatment. The products will be sold only in pharmacies. To the signing ceremony held; Teknopark Istanbul General Manager Bilal Topçu, Umayana Founder Biochemistry Specialist. Hülya Dağöttüren, Capa Medikal Chairman of the Board Zekeriya Avşar, Capa Medikal Board Member Sevim Öztaşkın and Gülbin Müftüoğlu attended.
“We contribute to serious projects”
Speaking at the signing ceremony, Teknopark Istanbul General Manager Bilal Topçu said, “We produce and contribute to the Turkish economy and the world with very serious projects. One of the units that we can call the engine that makes the most important contribution to this ecosystem is our Incubation and acceleration center. We, as Teknopark Istanbul, believe that we see the potential of our companies and entrepreneurs. While crowning the qualified projects carried out with deep technology in Technopark Istanbul with valuable outputs with the work we do, it motivates us and enables us to undertake new works in order to improve our processes. Teknopark Istanbul, which carries out R&D activities in many fields such as defense industry, cyber security, energy, artificial intelligence and robotic systems, and biotechnology, produces deep technology in nearly 3 thousand national projects with more than 400 companies and 9 thousand R&D engineers. I would like to thank Çapa Medikal and Umayana R&D officials for this cooperation.”
“We will do well”
Umayana Founder Biochemistry Specialist. In her speech, Hülya Dağöttüren said, “I would like to express that we have been directing our work by targeting the world markets in this project, which we have been working on since 2014, but we are extremely happy to cooperate with Çapa Medikal so that our products come out of our own country. We are confident that we will achieve good works because Capa Medikal has a deep-rooted and ethical business understanding and has made a name for itself not only in our country but also in international trade.”
6 important products will be produced
Dağöttüren continued his words as follows: “Dynamics of the pharmaceutical and medical industries are different. We need to follow the legislation on this subject from R&D studies until we bring it to the market, and it is necessary to set the target from the beginning and take every step with a well-planned approach while introducing the products to the market. Therefore, the R&D infrastructure offered by Teknopark Istanbul and its support in commercialization have been very valuable. The team is also important. Each team member must be well-equipped in their own field and of course the production must be done in accordance with the legislation. Umayana has a patented molecular compound produced with deep technology. With these patented formulas, we have proven, for the first time in the world, that we can prevent cancer scars with our clinical studies. We have 6 Murnia products in the fields of oncology, dermatology and dentistry. These products will be produced in the Sakarya plant of Honnes Health, a subsidiary of Çapa Medikal. My partner Gülbin Müftüoğlu, who lives in the USA, has a senior executive and marketing experience who has worked at Unilever, Nestle, J&J companies. He manages Umayana’s global strategies.”
To be sold in pharmacies
Zekeriya Avşar, Member of the Board of Capa Medikal, who said that 6 products will be produced in Honnes Health facilities in accordance with the ISO standards, said, “It is extremely important that the products reach the patient as much as they are patented and effective. With the sales and marketing team established by Çapa Medikal, the products will be promoted to health professionals and sold from pharmacies.”
Capa Medikal Board Member Sevim Öztaşkın also provided the following information: “With the Murnia brand, mucositis mouth gel, radiodermatitis cream and xerostomia (dry mouth solution) began to be offered to the market in the first place in the field of oncology. Mucositis is a common and unfortunately effective treatment for cancer patients receiving chemotherapy and radiotherapy. “Murnia mouth gel is the first product in the world with its preventive and therapeutic properties proven by clinical studies. This cooperation, which was signed for the first time in this field, shows how important a step is for our country and the world.”